Baricitinib in the Treatment of Adults With Pyoderma Gangrenosum (PG)
- Status
- COMPLETED
- Phase
- PHASE2
Clinical Trials Related to Baricitinib
Related studies linked through entity extraction aliases.
EU SolidAct: An Adaptive Pandemic and Emerging Infection Platform Trial
- Status
- TERMINATED
- Phase
- PHASE2/PHASE3
Baricitinib in New-onset Type 1 Diabetes
- Status
- COMPLETED
- Phase
- PHASE2
Efficacy of Ramdicivir and Baricitinib for the Treatment of Severe COVID 19 Patients
- Status
- UNKNOWN
- Phase
- PHASE3
Adaptive COVID-19 Treatment Trial 4 (ACTT-4)
- Status
- COMPLETED
- Phase
- PHASE3
A Study of Baricitinib (LY3009104) in Adult and Pediatric Japanese Participants With NNS/CANDLE, SAVI, and AGS
- Status
- TERMINATED
- Phase
- PHASE2/PHASE3
A Study of Baricitinib (LY3009104) in Participants With COVID-19
- Status
- COMPLETED
- Phase
- PHASE3
Adaptive COVID-19 Treatment Trial 2 (ACTT-2)
- Status
- COMPLETED
- Phase
- PHASE3
Baricitinib for coRona Virus pnEumonia (COVID-19): a THerapeutic Trial
- Status
- UNKNOWN
- Phase
- PHASE2
mulTi-Arm Therapeutic Study in Pre-ICu Patients Admitted With Covid-19 - Repurposed Drugs (TACTIC-R)
- Status
- UNKNOWN
- Phase
- PHASE4
Randomised Evaluation of COVID-19 Therapy
- Status
- RECRUITING
- Phase
- PHASE3
Baricitinib, Placebo and Antiviral Therapy for the Treatment of Patients With Moderate and Severe COVID-19
- Status
- TERMINATED
- Phase
- PHASE2
Safety and Efficacy of Baricitinib for COVID-19
- Status
- WITHDRAWN
- Phase
- PHASE2/PHASE3
Baricitinib in Symptomatic Patients Infected by COVID-19: an Open-label, Pilot Study.
- Status
- UNKNOWN
- Phase
- PHASE2/PHASE3
JAK 1/2 Inhibitor, Baricitinib, in the Treatment of Adult IIM
- Status
- COMPLETED
- Phase
- PHASE2
Baricitinib for the Prophylaxis of Graft-Versus-Host Disease After Peripheral Blood Hematopoietic Cell Transplantation
- Status
- COMPLETED
- Phase
- PHASE1
A Study of Baricitinib (LY3009104) in Participants From 2 Years to Less Than 18 Years Old With Active JIA-Associated Uveitis or Chronic Anterior Antinuclear Antibody-Positive Uveitis
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
A Study of Baricitinib (LY3009104) in Participants From 1 Year to Less Than 18 Years Old With Systemic Juvenile Idiopathic Arthritis (sJIA)
- Status
- RECRUITING
- Phase
- PHASE3
A Study of Baricitinib in Participants With Rheumatoid Arthritis
- Status
- COMPLETED
- Phase
- PHASE4
BAriCitinib Healing Effect in earLy pOlymyalgia Rheumatica
- Status
- COMPLETED
- Phase
- PHASE2